BlackRock Health Sciences Term Trust (NYSE:BMEZ) Director Robert Fairbairn Sells 10,294 Shares

BlackRock Health Sciences Term Trust (NYSE:BMEZ) Director Robert Fairbairn sold 10,294 shares of BlackRock Health Sciences Term Trust stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $14.98, for a total transaction of $154,204.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

BlackRock Health Sciences Term Trust Stock Performance

Shares of BlackRock Health Sciences Term Trust stock traded down $0.01 during trading hours on Monday, reaching $15.17. The company’s stock had a trading volume of 204,842 shares, compared to its average volume of 305,926. The firm has a 50 day moving average price of $15.04 and a 200-day moving average price of $14.57. BlackRock Health Sciences Term Trust has a one year low of $12.58 and a one year high of $16.75.

BlackRock Health Sciences Term Trust Dividend Announcement

The business also recently disclosed a monthly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 22nd will be given a dividend of $0.11 per share. The ex-dividend date is Monday, December 22nd. This represents a c) dividend on an annualized basis and a yield of 8.7%.

Institutional Investors Weigh In On BlackRock Health Sciences Term Trust

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Nova Wealth Management Inc. purchased a new position in BlackRock Health Sciences Term Trust in the first quarter worth $39,000. Geneos Wealth Management Inc. purchased a new position in BlackRock Health Sciences Term Trust during the 1st quarter worth $40,000. Allworth Financial LP increased its position in BlackRock Health Sciences Term Trust by 24,584.6% during the 3rd quarter. Allworth Financial LP now owns 3,209 shares of the company’s stock valued at $46,000 after buying an additional 3,196 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in BlackRock Health Sciences Term Trust during the 2nd quarter valued at about $69,000. Finally, Smartleaf Asset Management LLC purchased a new stake in BlackRock Health Sciences Term Trust in the third quarter valued at about $91,000.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Term Trust (NYSE: BMEZ) is a closed-end management investment company organized as a Delaware statutory trust. Launched in March 2020, BMEZ seeks to provide total return through a combination of current income and capital appreciation by investing primarily in equity and equity-related securities of companies in the health sciences sector. The trust is structured with a fixed termination date in October 2030, at which time shareholders will vote on its liquidation, extension or conversion.

The fund’s investment portfolio is diversified across subsectors within health sciences, including biotechnology, pharmaceuticals, medical devices, diagnostics and healthcare services.